RU2697651C2 - 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные - Google Patents

2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные Download PDF

Info

Publication number
RU2697651C2
RU2697651C2 RU2017104264A RU2017104264A RU2697651C2 RU 2697651 C2 RU2697651 C2 RU 2697651C2 RU 2017104264 A RU2017104264 A RU 2017104264A RU 2017104264 A RU2017104264 A RU 2017104264A RU 2697651 C2 RU2697651 C2 RU 2697651C2
Authority
RU
Russia
Prior art keywords
azabicyclo
oxa
heptan
phenyl
carboxamide
Prior art date
Application number
RU2017104264A
Other languages
English (en)
Russian (ru)
Other versions
RU2017104264A3 (zh
RU2017104264A (ru
Inventor
Джузеппе ЧЕЧЕРЕ
Гуидо Галлей
Иминь Ху
Роджер НОРКРОСС
Филипп ПФЛИГЕР
Хун Шэнь
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2017104264A publication Critical patent/RU2017104264A/ru
Publication of RU2017104264A3 publication Critical patent/RU2017104264A3/ru
Application granted granted Critical
Publication of RU2697651C2 publication Critical patent/RU2697651C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2017104264A 2014-08-01 2015-07-29 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные RU2697651C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2014/083549 WO2016015333A1 (en) 2014-08-01 2014-08-01 2-oxa-5-azabicyclo [2.2.1] heptan-3-yl derivatives
CNPCT/CN2014/083549 2014-08-01
PCT/EP2015/067353 WO2016016292A1 (en) 2014-08-01 2015-07-29 2-oxa-5-azabicyclo[2.2.1]heptan-3-yl derivatives

Publications (3)

Publication Number Publication Date
RU2017104264A RU2017104264A (ru) 2018-09-04
RU2017104264A3 RU2017104264A3 (zh) 2019-02-27
RU2697651C2 true RU2697651C2 (ru) 2019-08-16

Family

ID=53758230

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017104264A RU2697651C2 (ru) 2014-08-01 2015-07-29 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные

Country Status (11)

Country Link
US (1) US9790230B2 (zh)
EP (1) EP3174886B1 (zh)
JP (1) JP6364121B2 (zh)
KR (1) KR101911651B1 (zh)
CN (1) CN106661043B (zh)
AR (1) AR101359A1 (zh)
CA (1) CA2954209C (zh)
MX (1) MX2017001096A (zh)
RU (1) RU2697651C2 (zh)
TW (1) TWI583687B (zh)
WO (2) WO2016015333A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6814814B2 (ja) * 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
JP2019517524A (ja) * 2016-06-02 2019-06-24 パーデュー ファーマ エルピー 疼痛治療のための微量アミン関連受容体１アゴニスト及び部分アゴニスト
CN106187911A (zh) * 2016-07-04 2016-12-07 烟台凯博医药科技有限公司 2‑三氟甲基嘧啶‑4‑羧酸及其衍生物和制备方法
US20230416199A1 (en) * 2020-10-23 2023-12-28 Icahn School Of Medicine At Mount Sinai Inhibitors of amino acid transport
WO2023033679A1 (en) * 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») (azacycloalkyl)methoxy-substituted benzamides as modulators of trace amine-associated receptor 1 (taar1)
WO2023033680A1 (en) 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») Substituted 2,3,4,5-tetrahydrobenzo[ f][1,4]oxazepines as modulators of trace amine-associated receptor 1 (taar1)
WO2023033681A1 (en) 2021-09-01 2023-03-09 Limited Liability Company «Excellena Research And Development» (Llc «Excellena») Substituted 2-(5-aryl-4 h-1,2,4-triazol-3-yl)ethanamines as modulators of trace amine-associated receptor 1 (taar1)
WO2023156565A1 (en) * 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017802B1 (ru) * 2007-02-09 2013-03-29 Санофи-Авентис Азабициклоалкановые производные, их получение и их применение в терапии
WO2014072257A1 (en) * 2012-11-07 2014-05-15 F. Hoffmann-La Roche Ag Pyrazine derivatives
RU2016149984A (ru) * 2014-05-28 2018-07-02 Ф. Хоффманн-Ля Рош Аг Производные 5-окса-2-азабицикло[2.2.2]октан-4-ила и 5-окса-2-азабицикло[2.2.1]гептан-4-ила в качестве модуляторов taar1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1012172B (zh) * 1984-08-24 1991-03-27 北京医学科学院药物研究所 新型黄皮酰胺类化合物的分离和提取方法
DE3431257A1 (de) * 1984-08-24 1986-03-06 Bayer Ag, 5090 Leverkusen Neue (delta)-butyrolactame, pharmakologisch aktive zusammensetzungen derselben, verfahren zu ihrer herstellung und ihre medizinische verwendung
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA017802B1 (ru) * 2007-02-09 2013-03-29 Санофи-Авентис Азабициклоалкановые производные, их получение и их применение в терапии
WO2014072257A1 (en) * 2012-11-07 2014-05-15 F. Hoffmann-La Roche Ag Pyrazine derivatives
RU2016149984A (ru) * 2014-05-28 2018-07-02 Ф. Хоффманн-Ля Рош Аг Производные 5-окса-2-азабицикло[2.2.2]октан-4-ила и 5-окса-2-азабицикло[2.2.1]гептан-4-ила в качестве модуляторов taar1

Also Published As

Publication number Publication date
KR20170021352A (ko) 2017-02-27
RU2017104264A3 (zh) 2019-02-27
JP2017522353A (ja) 2017-08-10
CN106661043A (zh) 2017-05-10
AR101359A1 (es) 2016-12-14
CN106661043B (zh) 2020-01-17
MX2017001096A (es) 2017-04-27
EP3174886A1 (en) 2017-06-07
KR101911651B1 (ko) 2018-10-24
WO2016015333A1 (en) 2016-02-04
RU2017104264A (ru) 2018-09-04
TW201617349A (zh) 2016-05-16
EP3174886B1 (en) 2021-02-17
CA2954209C (en) 2022-08-30
JP6364121B2 (ja) 2018-07-25
TWI583687B (zh) 2017-05-21
US9790230B2 (en) 2017-10-17
BR112016028714A2 (pt) 2017-08-22
WO2016016292A1 (en) 2016-02-04
US20170137435A1 (en) 2017-05-18
CA2954209A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
RU2697651C2 (ru) 2-окса-5-азабицикло[2.2.1]гептан-3-ильные производные
US10023559B2 (en) Substituted azetidine derivatives
US9840501B2 (en) Morpholin-pyridine derivatives
US9663530B2 (en) 5-oxa-2-azabicyclo[2.2.2]OCTAN-4-yl and 5-oxa-2-azabicyclo[2.2.1]heptan-4-yl derivatives
KR20150065190A (ko) 피라진 유도체
WO2017018475A1 (ja) 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途
BR112016028714B1 (pt) Derivados de 2-oxa-5-azabiciclo[2.2.1] heptan-3-ila, seu uso e composição farmacêutica que os compreende